Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Legal & General Group Plc grew its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 22.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,144 shares of the specialty pharmaceutical company’s stock after buying an additional 1,494 shares during the period. Legal & General Group Plc’s holdings in KalVista Pharmaceuticals were worth $69,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of KalVista Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company’s stock worth $9,624,000 after buying an additional 24,713 shares in the last quarter. Barclays PLC grew its holdings in shares of KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 54,257 shares in the last quarter. JPMorgan Chase & Co. raised its stake in KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,670 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth approximately $634,000. Finally, SG Americas Securities LLC raised its position in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares during the period.

Analyst Ratings Changes

Several brokerages have issued reports on KALV. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Jones Trading reissued a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, JMP Securities started coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.83.

Insider Transactions at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was bought at an average cost of $9.22 per share, with a total value of $134,261.64. Following the purchase, the insider now owns 5,012,796 shares in the company, valued at approximately $46,217,979.12. The trade was a 0.29 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the sale, the insider now directly owns 100,334 shares in the company, valued at $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 217,348 shares of company stock valued at $2,014,773 and have sold 17,292 shares valued at $184,625. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $13.60 on Friday. The company has a market cap of $676.14 million, a P/E ratio of -3.74 and a beta of 0.39. The business’s 50-day simple moving average is $11.85 and its 200 day simple moving average is $10.42. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $15.50.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).